Vivani Medical, Inc. is a clinical-stage biotech focused on implantable drug delivery for chronic diseases like type 2 diabetes and obesity. Its key programs involve GLP-1 receptor agonist implants for exenatide and semaglutide, backed by ongoing clinical trials. The company continues to operate at significant net losses and negative cash flow, requiring frequent equity raises for funding its development activities. Future growth will hinge on successful regulatory approvals and commercialization milestones in an uncertain reimbursement and competitive environment.